Mangoceuticals (MGRX) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 was $168,109, up slightly from $163,163 in Q2 2024, driven by increased customers for MangoRx and PeachesRx products.

• Net loss for Q2 2025 widened to $5,415,820 from $2,391,319 in Q2 2024, mainly due to higher general and administrative expenses and increased stock-based compensation.

• The company continued to invest in intellectual property, entering and later rescinding several master distribution and IP agreements, and expanded its product portfolio.

• Significant equity and debt financing activities occurred, including private placements, warrant exercises, and convertible note conversions.

• As of June 30, 2025, the company had $101,019 in cash and a working capital deficit of $1.48 million, raising substantial doubt about its ability to continue as a going concern without additional funding.

Financial highlights

• Q2 2025 revenue: $168,109 (Q2 2024: $163,163); six-month revenue: $277,415 (2024: $377,258).

• Q2 2025 net loss: $5,415,820 (Q2 2024: $2,391,319); six-month net loss: $10,255,309 (2024: $4,758,936).

• Gross profit for Q2 2025: $89,948 (Q2 2024: $69,792); six-month gross profit: $152,012 (2024: $217,190).

• Operating expenses for Q2 2025: $5,358,443 (Q2 2024: $2,238,433); six-month operating expenses: $10,273,696 (2024: $4,753,448).

• Stock-based compensation for Q2 2025: $3,120,445 (Q2 2024: $859,380); six-month: $4,165,924 (2024: $1,313,845).

Outlook and guidance

• Management anticipates the need for additional funding to continue operations and execute growth plans over the next 12 months.

• The company plans to expand organically and through acquisitions, focusing on technology, health, and wellness sectors.

• Strategic alternatives, including mergers, acquisitions, and divestitures, are being evaluated to maximize shareholder value.